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Abstract
The major symptoms of Tourette syndrome are motor and vocal tics, but Tourette syndrome
is occasionally associated with cognitive alterations as well. Although Tourette syndrome
does not affect the majority of cognitive functions, some of them improve. There is scarce
evidence on the impairment of learning functions in patients with Tourette syndrome. The
core symptoms of Tourette syndrome are related to dysfunction of the basal ganglia and the
frontostriatal loops. Acquired equivalence learning is a kind of associative learning that is
related to the basal ganglia and the hippocampi. The modified Rutgers Acquired Equiva-
lence Test was used in the present study to observe the associative learning function of
patients with Tourette syndrome. The cognitive learning task can be divided into two main
phases: the acquisition and test phases. The latter is further divided into two parts: retrieval
and generalization. The acquisition phase of the associative learning test, which mainly
depends on the function of the basal ganglia, was affected in the entire patient group, which
included patients with Tourette syndrome with attention deficit hyperactivity disorder, obses-
sive compulsive disorder, autism spectrum disorder, or no comorbidities. Patients with Tour-
ette syndrome performed worse in building associations. However, the retrieval and
generalization parts of the test phase, which primarily depend on the function of the hippo-
campus, were not worsened by Tourette syndrome.
Introduction
Tourette syndrome (TS) is a disorder that presents before the age of 18 years, affecting 1% of
school-aged children [1–4]. The most frequent symptoms are motor and vocal tics [1, 5],
which significantly improve in many patients by young adulthood [6]. In addition to these pri-
mary symptoms, pure Tourette syndrome is associated with some mild alterations in cognitive
functions, mainly in a few executive functions (i.e., verbal fluency, working memory, and
Stroop effect), which extend into adulthood [7–9], and others, which disappear with age (i.e.,
deficits demonstrated by the Wisconsin Card Sorting Test [10]).
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Bodosi B, Giricz Z, et al. (2020) Impairment of
visually guided associative learning in children with
Tourette syndrome. PLoS ONE 15(6): e0234724.
https://doi.org/10.1371/journal.pone.0234724
Editor: Alexandra Kavushansky, Technion Israel
Institute of Technology, ISRAEL
Received: October 29, 2019
Accepted: June 2, 2020
Published: June 16, 2020
Peer Review History: PLOS recognizes the
benefits of transparency in the peer review
process; therefore, we enable the publication of
all of the content of peer review and author
responses alongside final, published articles. The
editorial history of this article is available here:
https://doi.org/10.1371/journal.pone.0234724
Copyright: © 2020 Eördegh et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the manuscript and its Supporting
Information files.
Funding: (AN) Faculty Research Fund, Albert
Szent-Györgyi Grant, Faculty of Medicine,
The symptoms of Tourette syndrome are mainly related to dysfunction of the basal gan-
glia and the connected frontal lobe [11, 12]. Reduced left caudate nucleus volume [13], pre-
frontal hypertrophy, and structural changes have been described in Tourette syndrome
[14–16]. The connection between the frontal lobe and the basal ganglia via parallel and
overlapping frontostriatal circuits [5, 12, 17–22] is significantly weaker in Tourette syn-
drome [23].
This frontostriatal system is responsible for motor functions and several cognitive functions
[24]. However, significant impairment of cognitive functions has only been rarely described in
patients with Tourette syndrome without any comorbidities [25], and the impairment often
depends on the level of tic severity [26–28]. Most impairment has been reported in Tourette
syndrome with its most frequent comorbidity, attention deficit hyperactivity disorder
(ADHD) [29–31]. Previous studies have emphasized that most alterations of cognitive func-
tions are primarily associated with concomitant ADHD and TS [32–36]. These results suggest
that the cognitive performance of patients with TS + ADHD is more similar to that of patients
with ADHD than that of patients with Tourette syndrome [33, 35, 37, 38]. Accordingly, Chan-
non et al. did not find any impairment in explicit or implicit memory or learning processes in
Tourette syndrome alone but did find these impairments in TS + ADHD [39]. In reinforce-
ment learning, the results are conflicting, but most results show no difference between patients
with Tourette syndrome and healthy controls [26, 40–43]. Patients with Tourette syndrome
have intact motor sequence learning [44], but the procedural (habit) learning in a probabilistic
classification learning, which is connected to the dorsal striatum [45] was significantly altered
[46, 47]. However, hippocampus-related learning was not affected in patients with Tourette
syndrome alone [47]. Another procedural learning type, implicit probabilistic sequence learn-
ing, was not affected or was even better in patients with Tourette syndrome [48, 49]. These
learning functions function via frontostriatal loops as well as associative learning, which has
not yet been investigated for Tourette syndrome.
Associative learning, in which discrete and often different signals are linked together, is a
type of conditioning. For example, when we remember a face, we record all the facial fea-
tures, and the parts reinforce each other. This basic cognitive function is related to basal gan-
glia and hippocampus functions. The Rutgers Acquired Equivalence Test [35] investigates
this specific learning ability. The primary advantage of this test is that each phase of the para-
digm has well-described neural substrates. The acquisition phase, which primarily depends
on the function of the basal ganglia [35, 50], tests the association of two different visual sti-
muli with the help of feedback about the correctness of the responses. In the test phase,
which primarily depends on the function of the hippocampus and the mediotemporal lobe
[35, 50], the previously learned associations are presented without any feedback (retrieval
part), and previously not presented but predictable associations (generalization part) are
shown. This learning function was previously investigated in adult patients with Parkinson’s
disease, Alzheimer’s disease, schizophrenia, and migraine without aura [35, 51–53] but never
in children with neurological or psychiatric disorders compared with healthy controls. Thus,
the description of this learning ability in Tourette syndrome remains missing. Since Tourette
syndrome is related to dysfunction of the basal ganglia and the frontostriatal loops, we
hypothesized that the acquisition phase could be primarily affected in the Acquired Equiva-
lence Test. Thus, the primary aim of the present study was to determine whether visually
guided associative acquired equivalence learning is affected in children with Tourette syn-
drome. We also investigated whether similar to other cognitive deficits of patients with Tour-
ette syndrome the ADHD is the primary reason for reduced associative learning ability in
patients with Tourette syndrome.
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Methods
Participants
Altogether, 46 children with Tourette syndrome participated in the present research. The
children were recruited from Vadaskert Child Psychiatry Hospital in Budapest, Hungary.
The children were diagnosed by both a licensed clinical psychologist and a board-certified
child psychiatrist at the hospital according to the Diagnostic and Statistical Manual of Mental
Disorders, Fifth Edition (DSM-V) criteria [1]. A total of 21 patients were diagnosed with
Tourette syndrome without any other neurological or psychiatric comorbidities (TS group);
15 were diagnosed with Tourette syndrome and comorbid ADHD (TS + ADHD group); and
10 were diagnosed with Tourette syndrome and some other comorbidity (obsessive compul-
sive disorder [OCD] or autism spectrum disorder [ASD]; TS + OCD/ASD group). In this
study, we analyzed associative learning of patients in the TS, TS + ADHD, and TS + OCD/
ASD groups in detail (32 boys and 14 girls, mean age: 11.64±2.38 years, age range: 8–17
years). Children with other neurodevelopmental or psychiatric comorbidities or learning dis-
abilities were excluded. The mean Yale Global Tic Severity Scale (YGTSS) total tic score
(TTS) was 20.7±6.4 (range: 8–33) [5, 54] in the whole patient group. Two participants showed
minimal tic severity (TTS� 10); 17 showed mild tic severity (score 11–20); and 19 showed
moderate to severe tic severity (score> 20). There were no significant differences (Kruskal–
Wallis ANOVA, p>0.05) among the patient subgroups according to age, IQ level, and tic
severity. Twelve of the children involved in this study (3 from the TS group, 6 from the TS
+ ADHD group, and 3 from the TS + OCD/ASD group) were medicated because of the
symptoms of their disorder. The TS group received dopamine 2 receptor antagonists (halo-
peridol and risperidone). The TS + ADHD patients received a norepinephrine–dopamine
reuptake inhibitor (methylphenidate), a dopamine 2 receptor antagonist (haloperidol), or a
partial agonist of the dopamine 2 and serotonin 1A receptors (aripiprazole), a norepineph-
rine transporter and dopamine reuptake inhibitor (atomoxetine), or melatonin. The TS
+ OCD/ASD group received selective serotonin reuptake inhibitors (fluvoxamine and sertra-
line), a partial agonist of the dopamine 2 and serotonin 1A receptors (aripiprazole), a seroto-
nin and dopamine antagonist (risperidone), or a norepinephrine-dopamine reuptake
inhibitor (methylphenidate).
The parents of all participants signed an informed consent form and did not receive finan-
cial compensation for their participation. The protocol of the study conformed to the tenets of
the Declaration of Helsinki in all respects, and it was approved by the Ministry of Human
Capacities in Budapest, Hungary (11818-6/2017/EÜIG).
From our database of control children recruited from local schools, 46 control children (31
boys and 15 girls, mean age: 11.55±2.38 years, range: 8–17.5 years) were assorted and individu-
ally matched based on sex, age (differing in age by no more than six months), and IQ level to
the patient groups. There were no significant differences (Kruskal–Wallis ANOVA, p>0.05)
among the control subgroups according to age and IQ level. Table 1 shows the demographic
data for the patient and control groups.
The control group only included children without any known psychiatric, neurological, or
neurodevelopmental disorders. All participants (patients and controls) had normal or cor-
rected-to-normal vision and normal hearing. The intactness of color vision was tested by Ishi-
hara plates prior to testing to exclude color blindness [55] both in the patient and control
groups. Only patients and controls with normal color vision were analyzed in the present
study. We estimated the IQ level with Raven’s Standard [56] and Colored [57] Progressive
Matrices [58].
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Visually guided associative learning paradigm
The principle of the visual learning paradigm is based on the Rutgers Acquired Equivalence
Test [35]. The original visual associative learning test [35] written for iOS (Apple Inc.’s operat-
ing system) was slightly modified, translated to Hungarian, and rewritten in Assembly (for
Windows) with the written permission of Prof. Catherine E. Myers (Rutgers University, NJ,
USA). The test was run on a PC. The testing sessions occurred in a dark and quiet room with
the participants sitting at a standard distance (114 cm) from the computer screen with com-
fortable visibility and legible brightness. The participants were asked to learn associations
between antecedent stimuli (four faces: A1, A2, B1, and B2) and consequent stimuli (four fish
with different colors: X1, X2, Y1, and Y2). The four possible faces were a male adult, a male
child, a female adult, and a female child. The four colors were red, green, blue, and yellow. The
antecedent-consequent pairings were randomly generated by the computer from these stimuli
for each participant. The acquired equivalence paradigm was structured as follows (Fig 1).
Acquisition phase. During each trial of the task, participants saw a face and a pair of fish
and had to learn through trial and error which of the fish matched which face. In the initial
training stages, participants were expected to learn that when face A1 or A2 appears, the cor-
rect choice is fish X1 over fish Y1; when face B1 or B2 appears, the correct choice is fish Y1
over fish X1. If the associations are successfully learned, participants also learn that faces A1
and A2 are equivalent with respect to the associated fish (faces B1 and B2 are likewise equiva-
lent with respect to the associated fish). Next, participants learned a new set of pairs: if pre-
sented with face A1, they had to choose fish X2 over Y2, and in the case of face B1, fish Y2 over
X2. Altogether, six stimulus combinations were shown in the acquisition phase of the para-
digm in which the computer provided feedback about the success of the acquisition after each
trial. New associations were individually introduced during the acquisition stages. New associ-
ations were mixed with trials of previously learned associations. The participants had to
achieve a certain number of consecutive correct responses after the presentation of each new
association (4 after the presentation of the first association, and 4, 6, 8, 10, and 12 with the
introduction of each new association, respectively) to be allowed to proceed. The number of
trials in the acquisition phase was not constant. It depended on the performance of the partici-
pant in learning the associations.
Test phase (retrieval and generalization parts). After successful acquisition, the partici-
pant continued with the test phase of the paradigm, in which no more feedback was provided
about the correctness of the choices. The participant had to recall the six previously built asso-
ciations (retrieval part) and had to make two new but predictable associations (generalization
part). In the generalization part of the test, the participant was asked to choose fish X2 or Y2
Table 1. Demographic parameters of the investigated groups.
Group Number of cases Male Age, mean ± SD (years) Age, range (years)
All patients 46 32 11.64±2.38 8–17
All controls 46 31 11.55±2.38 8–17.5
TS 21 14 11.74±2.26 9–17
TS controls 21 13 11.50±2.30 9–17
TS + ADHD 15 12 11.20±2.10 9–16.5
TS + ADHD controls 15 12 11.27±2.12 9–16
TS + OCD/ASD 10 6 12.10±2.84 8–17
TS + OCD/ASD controls 10 6 12.05±2.88 8–17.5
TS: Tourette syndrome, ADHD: attention deficit hyperactivity disorder, OCD/ASD: obsessive compulsive disorder or autism spectrum disorder.
https://doi.org/10.1371/journal.pone.0234724.t001
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when face A2 or B2 was presented. Having learned that faces A1 and A2 were equivalent in the
acquisition phase, participants may generalize from learning that if A1 goes with X2, A2 also
goes with X2; the same holds for B2 (equivalent to B1) and Y2 (associated with B1). In the test
phase, the new associations were mixed with the previously learned associations. The test
phase consistently contained 48 trials, including 36 previously built associations (retrieval
part) and 12 new, previously not presented but predictable associations (generalization part).
The participants’ task throughout the acquisition and testing phases was to indicate their
choice in each trial by pressing one of two keyboard buttons labeled LEFT and RIGHT.
Participants were tested individually without a time limit, so they could pay undivided
attention to learning. No forced quick responses were expected. While the formal description
may imply that the task was difficult, healthy children and intellectually disabled individuals
reliably make these kinds of generalizations.
Data analysis
The number of trials in the acquisition phase and the response accuracy (error ratios) in the
acquisition phase, the retrieval part of the test phase, and the generalization part of the test
phase were analyzed. We registered the number of trials required to complete the acquisition
phase (the number of acquisition trials [NAT]), the number of correct and incorrect choices
during the acquisition phase, and the number of correct and incorrect responses for known
and unknown associations during the retrieval and generalization parts of the test phase.
Using these data, the error ratios were calculated by dividing the number of incorrect
responses by the total number of responses provided. The proportion of the number of incor-
rect responses in the acquisition phase (the acquisition learning error ratio [ALER]), the num-
ber of incorrect responses divided by the total number of responses [36] in the retrieval part of
the test phase (i.e., the retrieval error ratio [RER]), and the number of incorrect responses
Fig 1. Graphic overview of the visually guided acquired equivalence learning paradigm. See details in Methods.
https://doi.org/10.1371/journal.pone.0234724.g001
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divided by the total number of responses [12] in the generalization part of the test phase (the
generalization error ratio [GER]) were measured.
Statistical analysis
First, we tested the distribution of our data. If the data sets were not normally distributed
according to the Shapiro–Wilk normality test, the comparisons between the performance of
patients with Tourette syndrome and that of control children were performed with the Mann–
Whitney rank test. A Kruskal–Wallis ANOVA was used to compare the performances of the
TS, TS + ADHD, and TS + OCD/ASD groups and to compare the performances of the control
subgroups, too. The median values and ranges are presented in the results section. If the data
were normally distributed according to the Shapiro–Wilk test but the homogeneity of the vari-
ance test revealed different variance in the performances of patients with Tourette syndrome
and that of healthy control children, Welch’s t-test was used to compare the two groups. The
mean and SD values are presented in the results section. Statistical analyses were performed in
Statistica 13.4.0.14 (1984–2018 TIBCO Software Inc., Palo Alto, CA, USA) and CogStat 1.8.0
and 1.9.0 (2012–2020 Attila Krajcsi).
Results
In this study, we present the performance of 46 pediatric patients with Tourette syndrome
with and without comorbidities and 46 matched healthy control children. All of the partici-
pants completed the entire visually guided acquired equivalence learning paradigm.
The performances of the entire Tourette syndrome group with and without
comorbidities versus healthy control children
In order to reduce the effect of multiple (twice in this case) application of the same data, the
statistical results were evaluated after Bonferroni correction at a significance level of 0.025. The
median NAT was 79.0 (range: 42–202, n = 46) in all patients with Tourette syndrome (with
and without medication) and 62.0 (range: 46–124, n = 46) in the control group. The NAT val-
ues were significantly higher in patients with Tourette syndrome (Mann–Whitney rank test
U = 636, p< 0.001). The median ALER was 0.102 (range: 0–0.325, n = 46) in all patients with
Tourette syndrome and 0.085 (range: 0–0.186, n = 46) in the control group. The ALER values,
similar to the NAT values, were significantly higher in patients with Tourette syndrome
(Mann–Whitney rank test U = 690, p = 0.004). In the retrieval part of the test phase, there was
no statistically significant difference (Mann–Whitney rank test U = 1.17e+0.3, p = 0.360)
between the patients with Tourette syndrome (median: 0.056, range: 0–0.333, n = 46) and the
control group (median: 0.083, range: 0–0.472, n = 46). In the generalization part of the test
phase, similar to the retrieval part, there was no statistically significant difference (Mann–
Whitney rank test U = 1.26e+0.3, p = 0.103) between the patients with Tourette syndrome
(median: 0.125, range: 0–0.667, n = 46) and the control group (median: 0.167, range: 0–0.917,
n = 46, Fig 2).
The effect of medication on the performances of patients with Tourette
syndrome with and without comorbidities
To examine the effects of medications on the performances in the applied associative learning
test, we compared the performances of the unmedicated patients (TS, TS + ADHD, and TS
+ OCD/ASD) and their matched healthy controls, the unmedicated patients with Tourette
PLOS ONE Learning impairment in Tourette syndrome
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syndrome and all patients with TS, and the medicated and unmedicated patients with Tourette
syndrome.
Unmedicated pediatric patients with Tourette syndrome versus healthy control chil-
dren. In order to reduce the effect of multiple (twice in this case) application of the same data
(first application was above in the comparison with the entire TS group), the statistical results
Fig 2. Performance of all patients with Tourette syndrome and healthy control children in the visually guided equivalence
learning paradigm. NAT denotes the number of the necessary trials in the acquisition phase of the paradigm. ALER shows the
error ratios in the acquisition phase of the paradigm. Lower diagrams denote the error ratios in the retrieval (RER) and
generalization (GER) parts of the test phase, respectively. In each panel, the first column (gray) shows the performance of all
patients with Tourette syndrome, and the second column (white) denotes the performance of the control group. The lower
margin of the boxes shows the 25th percentile; the line within the boxes marks the median; and the upper margin of the boxes
indicates the 75th percentile. The error bars (whiskers) above and below the boxes indicate the 90th and 10th percentiles,
respectively. The dots over and under the whiskers show the extreme outliers. The black stars indicate statistically significant
differences (p< 0.05).
https://doi.org/10.1371/journal.pone.0234724.g002
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were evaluated after Bonferroni correction at a significance level of 0.025. The median NAT
was 78.5 (range: 42–202, n = 34) in all unmedicated patients and 60.5 (range: 46–124, n = 34)
in the matched control group. The NAT values were significantly higher in patients with Tour-
ette syndrome (Mann–Whitney rank test, U = 345, p = 0.004). The median ALER was 0.102
(range: 0–0.325, n = 34) in patients with Tourette syndrome and 0.086 (range: 0–0.186, n = 34)
in the control group. The ALER values, similar to NAT values, were significant higher in
patients with Tourette syndrome (Mann–Whitney rank test U = 392, p = 0.023). In the
retrieval part of the test phase, there was no statistically significant difference (Mann–Whitney
rank test U = 657, p = 0.330) between the TS group (median: 0.056, range: 0–0.333) and the
control group (median: 0.083, range: 0–0.472). In the generalization part of the test phase,
there was no statistically significant difference (Mann–Whitney rank test U = 734, p = 0.053)
between the patients with Tourette syndrome (median: 0.083, range: 0–0.667) and the control
group (median: 0.208, range: 0–0.917, Fig 3)
All pediatric patients with Tourette syndrome versus unmedicated patients with Tourette
syndrome. Comparing the performances of the whole patient group (TS, TS + ADHD, and TS
+ OCD/ASD) with the unmedicated patient group (TS, TS + ADHD, and TS + OCD/ASD), we
did not find any significant differences. The median NAT was 79.0 (range: 42–202, n = 46) in the
whole patient group and 78.5 (range: 42–202, n = 34) in the unmedicated patient group. There
was no significant difference in the NAT between these groups (Mann–Whitney rank test
U = 763, p = 0.857). The median ALER was 0.102 (range: 0–0.325, n = 34) in the whole patient
group and 0.102 (range: 0–0.325, n = 34) in the unmedicated patient group. The ALER values, sim-
ilar to the NAT values, did not significantly differ (Mann–Whitney rank test U = 786, p = 0.969).
In the retrieval part of the test phase, the median RER was 0.056 in the whole patient group (range:
0–0.333, n = 46) and 0.056 (range: 0–0.333, n = 34) in the unmedicated patient group, and this dif-
ference was not statistically significant (Mann–Whitney rank test U = 774, p = 0.937). In the gener-
alization part of the test phase, the median GER was 0.125 in the whole patient group (range:
0–0.667, n = 46) and 0.083 (range: 0–0.667, n = 34) in the unmedicated patient group and this dif-
ference was not statistically significant (Mann–Whitney rank test U = 742, p = 0.698).
Medicated versus unmedicated pediatric patients with Tourette syndrome. The perfor-
mance of the medicated patient group did not differ significantly from the performance of the
unmedicated patient group. The median NAT was 79.0 (range: 68–101, n = 12) for the medi-
cated patient group and 78.5 (range: 42–202, n = 34) for the unmedicated patient group. There
was no statistically significant difference in the NAT between these groups (Mann–Whitney
rank test U = 185, p = 0.643). The median ALER was 0.106 (range: 0.056–0.250, n = 12) in the
medicated patient group and 0.102 (range: 0–0.325, n = 34) in the unmedicated patient group.
The ALER values, similar to the NAT values, did not significantly differ (Mann–Whitney rank
test U = 208, p = 0.920). In the retrieval part of the test phase, the median RER was 0.083 in the
medicated patient group (range: 0–0.139, n = 12) and 0.056 (range: 0–0.333, n = 34) in the
unmedicated patient group, and this difference was not statistically significant (Mann–Whit-
ney U test U = 196, p = 0.840). In the generalization part of the test phase, the median GER
was 0.208 in the medicated patient group (range: 0–0.667, n = 12) and 0.083 (range: 0–0.667,
n = 34) in the unmedicated patient group, and the difference was not statistically significant
(Mann–Whitney rank test U = 164, p = 0.319).
Comparison of the performances among the patients with TS, TS + ADHD,
and TS + OCD/ASD
In the first step we have compared the performances in one multiple comparison of the three
TS patient and the three control subgroups with Kruskal–Wallis ANOVA analysis. These
PLOS ONE Learning impairment in Tourette syndrome
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results revealed significant differences among the six subgroups in NAT (χ2 (5, N = 92) =
14.1829, p = 0.0145) and ALER (χ2 (5, N = 92) = 11.7513, p = 0.0384) but not in RER (χ2 (5,
N = 92) = 1.9133, p = 0.861) and GER (χ2 (5, N = 92) = 3.3317, p = 0.6490). In the next step we
have compared the performances among the three TS patient subgroups. There were no signif-
icant differences in the performances of the three patient groups (TS, TS + ADHD, and
Fig 3. Performance of the unmedicated pediatric patients with Tourette syndrome versus that of healthy control children
in the visually guided equivalence learning paradigm. NAT denotes the number of the necessary trials in the acquisition phase
of the paradigm. ALER shows the error ratios in the acquisition phase of the paradigm. Lower diagrams denote the error ratios
in the retrieval (RER) and generalization (GER) parts of the test phase, respectively. In each panel, the first column (gray) shows
the performance of all unmedicated patients with Tourette syndrome, and the second column (white) denotes the performance
of the control group. The lower margin of the boxes shows the 25th percentile; the line within the boxes marks the median; and
the upper margin of the boxes indicates the 75th percentile. The error bars (whiskers) above and below the boxes indicate the
90th and 10th percentiles, respectively. The dots over and under the whiskers show the extreme outliers. The black stars indicate
statistically significant differences (p< 0.05).
https://doi.org/10.1371/journal.pone.0234724.g003
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TS + OCD/ASD with or without medication) for any of the investigated parameters. The
results of the comparisons are shown in Table 2.
After the subtraction of the performances of the medicated patients from the analysis, there
were no significant differences among the TS, TS + ADHD, and TS + OCD/ASD groups
(Table 3).
To avoid the significant effect of the different performances of the three different control
subgroups we have compared the performances of the control subgroups, too. We have found
no significant differences in each of the investigated values among the control subgroups
(Kruskal–Wallis ANOVA, NAT: χ2 (2, N = 46) = 3.7562, p = 0.153; ALER: χ2 (2, N = 46) =
3.5641, p = 0.168; RER: χ2 (2, N = 46) = 0.7136, p = 0.965; GER: χ2 (2, N = 46) = 0.16242,
p = 0.922).
Performance of the three TS groups versus their matched healthy control
groups
To determine whether the significant findings described above originated in a similar manner
for patients with Tourette syndrome without comorbidities and for patients with Tourette syn-
drome and comorbidities (TS + ADHD or TS + OCD/ASD) we separately compared the data
of these three subpopulations with their matched healthy control groups.
Children with Tourette syndrome without any comorbidities versus healthy control
children. We examined the difference between the performance of patients with Tourette
syndrome and that of matched healthy controls. The median NAT was 79.0 (range: 52–130,
n = 21) in the TS group and 60.0 (range: 46–124, n = 21) in the control group. The NAT was
significantly higher in patients with Tourette syndrome (Mann–Whitney rank test U = 109,
p = 0.005). The median ALER of patients with Tourette syndrome was 0.101 (range: 0.018–
0.325, n = 21), and that of the healthy control group was 0.083 (range: 0–0.186, n = 21). The
Table 2. The performances of the Tourette syndrome, Tourette syndrome and attention deficit hyperactivity disorder, and Tourette syndrome and obsessive com-
pulsive disorder or autism spectrum disorder groups (with or without medication).
TS (n = 21) TS + ADHD (n = 15) TS + OCD/ASD (n = 10) Kruskal–Wallis test
NAT median: 79 range: 52–130 median: 78 range: 42–202 median:72 range: 46–169 χ2(2, N = 46) = 0.0498, p = 0.975
ALER median: 0.101 range: 0.018–0.325 median: 0.120 range: 0–0.287 median: 0.106 range:0.043–0.172 χ2(2, N = 46) = 1.13, p = 0.568
RER median: 0.056 range: 0–0.333 median: 0.056 range: 0.028–0.222 median: 0.097 range: 0.028–0.222 χ2(2, N = 46) = 1.1, p = 0.577
GER median: 0.083 range: 0–0.667 median: 0.167 range: 0–0.667 median: 0.208 range: 0–0.583 χ2(2, N = 46) = 0.389 p = 0.823
TS: Tourette syndrome, ADHD: attention deficit hyperactivity disorder, OCD/ASD: obsessive compulsive disorder or autism spectrum disorder, NAT: the number of
the necessary trials in the acquisition phase of the paradigm, ALER: the error ratios in the acquisition phase of the paradigm, RER: the error ratios in the retrieval part of
the test phase, and GER: the error ratio in the generalization part of the test phase.
https://doi.org/10.1371/journal.pone.0234724.t002
Table 3. The performances of the three unmedicated patient groups.
TS (n = 18) TS + ADHD (n = 9) TS + OCD/ASD (n = 7) Kruskal–Wallis test
NAT median: 79,5 range: 52–130 median: 62 range: 42–202 median: 89 range: 46–169 χ2(2, N = 34) = 0.877, p = 0.645
ALER median: 0.102 range: 0.018–0.325 median: 0.097 range: 0–0.287 median: 0.136 range: 0.043–0.172 χ2(2, N = 34) = 0.694, p = 0.707
RER median: 0.056 range: 0–0.333 median: 0.056 range: 0.028–0.222 median: 0.028 range: 0.028–0.222 χ2(2, N = 34) = 0.535, p = 0.765
GER median: 0.083 range: 0–0.667 median: 0.083 range: 0–0.161 median: 0.167 range: 0–0.583 χ2(2, N = 34) = 0.255, p = 0.880
TS: Tourette syndrome, ADHD: attention deficit hyperactivity disorder, OCD/ASD: obsessive compulsive disorder or autism spectrum disorder, NAT: the number of
the necessary trials in the acquisition phase of the paradigm, ALER: the error ratios in the acquisition phase of the paradigm, RER: the error ratios in the retrieval part of
the test phase, and GER: the error ratio in the generalization part of the test phase.
https://doi.org/10.1371/journal.pone.0234724.t003
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ALER values, similar to the NAT values, were higher in the TS group (Mann–Whitney rank
test U = 142, p = 0.049). In the retrieval part of the test phase, the median RER in the TS group
was 0.056, (range: 0–0.333, n = 21) and that in the matched healthy group was 0.083 (range:
0–0.361, n = 21). Although the RER was smaller in the Tourette syndrome group, this differ-
ence was not statistically significant (Mann–Whitney rank test U = 260, p = 0.327). In the gen-
eralization part of the test phase, the median GER was 0.083 (range: 0–0.667, n = 21) in the
group of patients with Tourette syndrome and 0.167 (range: 0–0.917, n = 21) in the healthy
control group. This difference was not statistically significant (Mann–Whitney rank test
U = 270, p = 0.209, Fig 4).
Patients with TS + ADHD versus healthy controls. These comparisons revealed the
same tendencies as those in the TS without any comorbidities and TS+OCD/ASD groups. The
NAT and ALER values were higher in the TS + ADHD than in the control group, while the
RER and GER values were lower in patients with TS+ADHD, but these differences did not sig-
nificantly differ from those values of the matched control children. The median NAT was 78.0
(range: 42–202, n = 15) in the TS + ADHD group and 75.0 (range: 45–97, n = 15; Mann–Whit-
ney rank test U = 89, p = 0.340) in the matched healthy control group. The median ALER was
0.120 (range: 0.0–0.287, n = 21) in the TS + ADHD group and 0.105 (range: 0.056–0.143,
n = 15, Welch’s test t(22,2) = -1.56, p = 0.138) in the control group. In the retrieval part of the
test phase, the median RER was 0.056 (range: 0.028–0.222, n = 15) in the TS + ADHD group
and 0.083 (range: 0.0–0.472, n = 15, Mann–Whitney rank test U = 120, p = 0.784) in the con-
trol group. In the generalization part of the test phase, the median GER was 0.167 (range:
0–0.667, n = 15) in the TS + ADHD group and 0.167 (range: 0–0.917, n = 15, Mann–Whitney
rank test U = 140, p = 0.255) in the matched healthy control group (Fig 5).
Patients with TS + OCD/ASD versus healthy controls. This comparison revealed the
same significant differences as were demonstrated above by the patients with Tourette syn-
drome without any comorbidities. The NAT and ALER values were significantly higher in the
TS + OCD/ASD group than in the control group, while the RER and GER values did not differ
between the TS + OCD/ASD and control groups. The median NAT was 72.0 (range: 46–169,
n = 10) in the TS + OCD/ASD group and 60.5 (range: 49–84, n = 10; independent samples t-
test t(18) = -2.21, p = 0.041) in the matched healthy control group. The median ALER was
0.106 (range: 0.043–0.172, n = 10) in the TS + OCD/ASD group and 0.083 (range: 0.019–0.125,
n = 10, independent samples t-test t(18) = -2.48, p = 0.023) in the control group. In the
retrieval part of the test phase, the median RER was 0.097 (range: 0.028–0.222, n = 10) in the
TS + OCD/ASD group and 0.083 (range: 0.027–0.250, n = 10, independent samples t-test t(18)
= 0.335, p = 0.741) in the control group. In the generalization part of the test phase, the median
GER was 0.208 (range: 0–0.583, n = 10) in the TS + OCD/ASD group and 0.208 (range:
0–0.750, n = 10, Mann–Whitney rank test U = 51.5, p = 0.939) in the matched healthy control
group (Fig 6).
Discussion
The Rutgers Acquired Equivalence Test (face and fish test, [35]), which investigates visually
guided associative learning in humans, has a well-defined neurological background. The
acquisition phase, which primarily depends on the function of the basal ganglia [35, 50] tests
the association between two different visual stimuli. The test phase, in which the previously
learned associations (retrieval part) and new, but acquisition-based, predictable associations
(generalization part) are evaluated, primarily depends on the hippocampi and the mediotem-
poral lobe [35, 50]. These cognitive functions were previously investigated in adult neurologi-
cal and psychiatric patients which were shown to be related to dysfunction of the basal ganglia
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and the hippocampi (i.e., Parkinson’s disease [34, 35], Alzheimer’s disease [51], and migraine
without aura [53]). However, the present study is the first to describe the alteration of visual
associative learning in a group of children with Tourette syndrome with and without comor-
bidities. This finding is interesting because only in rare cases have significant impairments in
Fig 4. Performance of the patients with Tourette syndrome without comorbidities versus that of matched healthy control
children in the visually guided equivalence learning paradigm. NAT denotes the number of the necessary trials in the
acquisition phase of the paradigm. ALER shows the error ratios in the acquisition phase of the paradigm. Lower diagrams denote
the error ratios in the retrieval (RER) and generalization (GER) parts of the test phase, respectively. In each panel, the first
column (gray) shows the performance of the patients with Tourette syndrome without comorbidities, and the second column
(white) denotes the performance of the control group. The lower margin of the boxes shows the 25th percentile; the line within
the boxes marks the median; and the upper margin of the boxes indicates the 75th percentile. The error bars (whiskers) above
and below the boxes indicate the 90th and 10th percentiles, respectively. The dots over and under the whiskers show the extreme
outliers. The black stars indicate statistically significant differences (p< 0.05).
https://doi.org/10.1371/journal.pone.0234724.g004
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any cognitive functions been described in Tourette syndrome. Tourette syndrome is strongly
related to dysfunction of the basal ganglia and the frontal associative cortex. Because of the
involvement of the basal ganglia in the pathogenesis of Tourette syndrome, the acquisition
phase, which mainly depends on the basal ganglia, was primarily affected in the associative
Fig 5. Performance of patients with concomitant Tourette syndrome and attention deficit hyperactivity disorder patients
versus that in matched healthy control children in the visually guided equivalence learning paradigm. NAT denotes the
number of the necessary trials in the acquisition phase of the paradigm. ALER shows the error ratios in the acquisition phase of
the paradigm. Lower diagrams denote the error ratios in the retrieval (RER) and generalization (GER) parts of the test phase,
respectively. In each panel, the first column (gray) shows the performance of the patients with Tourette syndrome (TS) and
attention deficit hyperactivity disorder (ADHD), and the second column (white) denotes the performance of the control group.
The lower margin of the boxes shows the 25th percentile; the line within the boxes marks the median; and the upper margin of
the boxes indicates the 75th percentile. The error bars (whiskers) above and below the boxes indicate the 90th and 10th
percentiles, respectively. The dots over and under the whiskers show the extreme outliers. The black stars indicate statistically
significant differences (p< 0.05).
https://doi.org/10.1371/journal.pone.0234724.g005
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learning test. Based on our results, all patients with Tourette syndrome made the associations
with less effectiveness than healthy control children. However, the retrieval and generalization
parts of the test phase, which primarily depend on the function of the hippocampi, were not
negatively affected by Tourette syndrome. Because of the compensation of the weaker
Fig 6. Performance of patients with concomitant Tourette syndrome and obsessive compulsive disorder or autism spectrum
disorder versus that of matched healthy control children in the visually guided equivalence learning paradigm. NAT denotes
the number of the necessary trials in the acquisition phase of the paradigm. ALER shows the error ratios in the acquisition phase
of the paradigm. Lower diagrams denote the error ratios in the retrieval (RER) and generalization (GER) parts of the test phase,
respectively. In each panel, the first column (gray) shows the performance of the patients with Tourette syndrome (TS) and
obsessive compulsive disorder (OCD) or autism spectrum disorder (ASD), and the second column (white) denotes the
performance of the control group. The lower margin of the boxes shows the 25th percentile; the line within the boxes marks the
median; and the upper margin of the boxes indicates the 75th percentile. The error bars (whiskers) above and below the boxes
indicate the 90th and 10th percentiles, respectively. The dots over and under the whiskers show the extreme outliers. The black
stars indicate statistically significant differences (p< 0.05).
https://doi.org/10.1371/journal.pone.0234724.g006
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acquisition building, even better performances were found in these phases of the paradigm,
although these differences were not statistically significant [36, 47].
Our results demonstrated that in the acquisition phase, the performance (NAT and ALER)
of all patients (TS, TS + ADHD, and TS + OCD/ASD) was significantly weaker than in the sex,
age, and IQ level-matched healthy control group. The question arises whether the alterations
in equivalence learning in all patients with Tourette syndrome were primarily due to TS or its
most common comorbidity, ADHD. In most cases, Tourette syndrome and ADHD, which
seems to plays a major role, are jointly responsible for the alterations in cognitive functions
[44, 59–61]. We compared the performances of the three patient groups and found no signifi-
cant difference among their performances. This finding does not support the predominant
role of ADHD in the described alterations in the acquisition phase of the associative learning
task. The comparison of each patient group with its matched healthy control group revealed
significantly increased NAT or ALER values in patients with Tourette syndrome without any
comorbidities and TS + OCD/ASD but not in patients with TS + ADHD. These results
together could suggest that concomitant ADHD and TS was not primarily responsible for the
visual acquisition learning deficits in patients with Tourette syndrome. This is in contrast with
previous findings that ADHD is primarily responsible for the alteration of cognitive functions
in patients with TS + ADHD [33, 37, 38, 43]. Therefore, the visually guided acquired equiva-
lence learning, similar to stimulus-response or habit learning [24, 45], which is mediated by
the dorsal frontostriatal pathways, is more attributable to Tourette syndrome than ADHD,
despite ADHD symptoms affecting the dorsolateral frontostriatal circuits [62].
The volume of the hippocampi is significantly larger in patients with pure Tourette syn-
drome than that of their healthy counterparts [63], and no explicit memory (which is con-
nected to the hippocampus) deficits were reported in children with Tourette syndrome [45,
47]. Our results are in line with these findings. The performance in the retrieval and generali-
zation parts of the test phase, which are primarily related to the hippocampi was not worse in
the entire group of patients with Tourette syndrome with and without comorbidities. Con-
cerning the three investigated subpopulations of the patients with Tourette syndrome (TS
without comorbidities, TS + ADHD, and TS + OCD/ASD), the RER and GER values did not
differ from those of the matched healthy control children.
Another question is the possible influence of medication on the performance of patients
with Tourette syndrome with or without comorbidities. Because of the relatively low number of
cases in the comorbid groups, we could not perform a valid comparison between the performance
of medicated and unmedicated TS + ADHD and TS + OCD/ASD patients. Thus, we used the
entire TS population (TS without comorbidities, TS + ADHD, and TS + OCD/ASD) to get infor-
mation about the possible role of medication. The performances in the acquisition phase of the
associative learning task in unmedicated TS pediatric patients, similar to the entire TS population,
were significantly weaker than those of the matched healthy control children. The comparison of
the performances of the entire and the unmedicated TS patient groups revealed no differences.
Similarly, we found no differences between the performances of the entire population of medi-
cated and unmedicated pediatric patients with Tourette syndrome. These findings collectively
suggest that medication had no or only a weak influence on our results.
In this study, we functionally confirmed the results of neuroimaging [14–16, 23] and
functional studies that the dorsal frontostriatal circuits are strongly affected in Tourette syn-
drome, and these circuits are critical to the acquisition process of visually guided associative
learning [46, 47]. The hippocampus mediated recall of previously learned associations, and the
building of new but acquisition-based, predictable associations were not altered in Tourette
syndrome.
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Supporting information
S1 Table. The data of the psychophysical performances of 46 TS patients and the 46
matched controls, which were used in the present study. TS: Tourette syndrome, ADHD:
attention deficit hyperactivity disorder, OCD/ASD: obsessive compulsive disorder or autism
spectrum disorder, NAT: the number of the necessary trials in the acquisition phase of the par-
adigm, ALER: the error ratios in the acquisition phase of the paradigm, RER: the error ratios
in the retrieval part of the test phase, and GER: the error ratio in the generalization part of the
test phase.
(XLSX)
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